GSK welcomes agreement with the Government of Canada for the provision of pandemic and seasonal influenza vaccines

GSK today announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine). Both vaccines will be supplied by GSK’s Sainte-Foy, Quebec facility. This agreement follows earlier agreements between the Government of Canada and GSK to supply both pandemic and seasonal influenza vaccines dating back to 2001.

NewsGuest UserAugust 29, 2022BIOOQuébecBIOQuébec, GSK, Vaccines

Medicago to launch clinical trials for COVID-19 vaccine candidate with GSK's pandemic adjuvant in Japan

This Japanese study, in combination with final data from the global Phase 2/3 study of the vaccine candidate, will be used to support an application for regulatory approval in Japan by March of 2022.

NewsGuest UserOctober 21, 2021COVID-19, Vaccines, Medicago, GSK

Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate

QUEBEC CITY and LONDON, May 18, 2021 /CNW/ - Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago's plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK's pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing. Immunogenicity, as measured by the neutralizing antibody titer, was high - about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration.

NewsGuest UserMay 18, 2021Medicago, GSK, COVID-19 vaccine

Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

QUEBEC CITY and LONDON, March 16, 2021 /CNW/ - Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline (GSK), are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval from Canadian and US regulatory authorities to proceed with enrollment of healthy adults in the Phase 3 portion of the trial based on positive interim Phase 2 results. In parallel, Medicago has also initiated a feasibility study of a vaccine candidate to address the emerging COVID-19 variants.

NewsGuest UserMarch 16, 2021COVID-19, vaccine, Medicago, GSK